アルツハイマー病と認知症のジャーナル オープンアクセス

抽象的な

Advances in determination of Alzheimer amyloid peptide

Maotian Xu & Yintang Zhang

Alzheimer???s disease (AD), the most common type of dementia in the elderly, is a progressive and devastating neurodegenerative disease causing memory loss, impaired thinking and other symptoms. ?-amyloid peptide (A?) indicates a biomarker for an AD in cerebrospinal fluid, blood, plasma and serum. Therefore, it is important to determine the A? concentration for early diagnosis and treatment of AD. In this study, micellar electrokinetic capillary chromatography (MEKC) combined with an online preconcentration method sweeping was established to determine A?1-42. Electrophoresis was carried out at a constant voltage of 5 kV in an uncoated fused-silica capillary. The 15 mmol/L borate buffer containing 20 mmol/L sodium dodecyl sulfate (SDS) with pH 9.3 was used as the running buffer. The samples were injected into the capillary by applying a pressure of 50 mbar for 60s. Under the optimal conditions, the detection limit of A?1-42 was as low as 0.08 ?mol/L. The recoveries of the normal addition method in real human serum sample analysis were found to be between 89.2% and 98.5%. The relative standard deviation (RSD) of the determination was less than 6%.